Abstract Number: 246 • 2019 ACR/ARP Annual Meeting
Smoking Exposure in Pack-Years Predicts Cutaneous Manifestations of Lupus
Background/Purpose: Patients of color are more likely to have systemic lupus erythematosus (SLE) and a smoking history. Prior literature notes that both smoking and race…Abstract Number: 465 • 2018 ACR/ARHP Annual Meeting
Seasonal Variation in Cutaneous Flares for Pediatric Lupus
Background/Purpose: Exposure to sunlight has been proposed as a possible environmental trigger for lupus flares, particularly cutaneous disease. Contradictory findings exist regarding seasonal variation in…Abstract Number: 2284 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Lenabasum in Refractory Skin-Predominant Dermatomyositis Subjects Treated on an Open-Label Extension of Trial JBT101-DM-001
Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses. Lenabasum had acceptable safety and tolerability…Abstract Number: 2287 • 2018 ACR/ARHP Annual Meeting
Interim Results of an Open-Label Study Assessing Efficacy and Safety of Adrenocorticotropic Hormone Gel for Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
Background/Purpose: Cutaneous dermatomyositis (DM) is often refractory to multiple medications, suggesting better treatments are needed. Adrenocorticotropic hormone gel is a repository corticotropin injection that is…Abstract Number: 2853 • 2018 ACR/ARHP Annual Meeting
A Protective Langerhans Cell-Keratinocyte Axis That Is Dysfunctional in Photosensitivity
Background/Purpose: Photosensitivity, or skin sensitivity to ultraviolet radiation (UVR), is a feature of lupus erythematosus (LE) and other autoimmune conditions. Photosensitive lesions can be disfiguring…Abstract Number: 2977 • 2018 ACR/ARHP Annual Meeting
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Reduces T-Cell Population and Downregulates Type 1 and 2 Interferon Activities in Lesional Dermatomyositis Skin
Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 (CB2) agonist that activates resolution of innate immune responses. CB2 is a G-protein coupled…Abstract Number: 2156 • 2017 ACR/ARHP Annual Meeting
Comparison of Patients with Dermatomyositis in a Specialty Clinic Versus Clinical Trial with Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist
Background/Purpose: There are limited treatment options and no published double-blind randomized placebo-controlled trials for the treatment of skin manifestations of dermatomyositis (DM). There is no…Abstract Number: 2157 • 2017 ACR/ARHP Annual Meeting
Factors Associated with Clinical Remission of Skin Disease in Dermatomyositis
Background/Purpose: Quantitative estimates of the duration and severity of cutaneous disease are lacking for adult dermatomyositis (DM) patients. The Cutaneous Dermatomyositis Disease Area and Severity…Abstract Number: 2749 • 2017 ACR/ARHP Annual Meeting
Four-Distinct Phenotypes of Patients with Necrotizing Arteritis of Medium and Small Arteries
Background/Purpose: Polyarteritis nodosa (PAN) is a necrotizing arteritis of medium and small arteries. PAN is divided into systemic and cutaneous PAN (cPAN). cPAN can be…Abstract Number: 1186 • 2016 ACR/ARHP Annual Meeting
The Use of Clinical Mucosal Manifestations to Differentiate Patients with Lupus and Dermatomyositis: Transversal, Retrospective and Analytical Study of 116 Patients
Background/Purpose: There are few studies comparing oral manifestations in patients with Cutaneous Lupus (CL), Systemic Lupus Erythematosus (SLE) and Dermatomyositis (DM). Our objective was to…Abstract Number: 1949 • 2016 ACR/ARHP Annual Meeting
Presentation, Prognosis and Clinical-Pathological Correlations of Cutaneous Manifestations in ANCA-Associated Vasculitides
Background/Purpose: Cutaneous involvement is frequent during ANCA-associated vasculitis (AAV) and can reveal the disease. However, no large study on presentation and clinical-pathological correlations is available.…Abstract Number: 2969 • 2016 ACR/ARHP Annual Meeting
10 Year Retrospective Analysis of 276 Cases of Histopathologically Confirmed Leukocytoclastic Vasculitis
Background/Purpose: We identified leukocytoclastic vasculitis (LCV) patients seen over 10 years at our institution. Aims included 1) define cause; 2) record lab, imaging, and ancillary…Abstract Number: 1462 • 2015 ACR/ARHP Annual Meeting
Farber Disease: Important Differential Diagnostic Information for JIA and Other Inflammatory Arthritis Phenotypes Is Revealed By Data from the Largest Clinical Cohort to Date
Background/Purpose: Farber disease (Farber lipogranulomatosis; acid ceramidase deficiency) is a rare lysosomal storage disorder resulting from the inherited deficiency of the enzyme acid ceramidase due…Abstract Number: 3033 • 2015 ACR/ARHP Annual Meeting
Polyarteritis Nodosa and Cutaneous Arteritis: Are They Distinct Diseases?
Background/Purpose: Polyarteritis nodosa (PAN) is a rare systemic necrotizing vasculitis predominantly targeting medium-sized visceral arteries. Cutaneous arteritis (CA) is generally limited to the medium-sized vessels…Abstract Number: 62 • 2015 ACR/ARHP Annual Meeting
Patient Perception of Disease Burden in Diffuse Cutaneous Systemic Sclerosis
Background/Purpose: Diffuse cutaneous SSc (dcSSc) is associated with high morbidity and mortality, and reduced quality of life. Patient priorities are rarely discussed, with physicians traditionally…
ACR Meeting Abstracts